EX-99.1 10 exhibit99.htm PRESS RELEASE ANNOUNCING 2Q RESULTS exhibit99.htm


PRESS RELEASE
LIFE SCIENCES RESEARCH, INC.
 
(NYSE Arca: LSR)
 
PO Box 2360
 
Mettlers Road
 
East Millstone, NJ  08875-2360
   
 
For Further Information:
 
Richard Michaelson
 
Phone: US (732) 649-9961
 
e-mail: LifeSciencesResearch@LSRinc.net

July 30, 2009

LSR ANNOUNCES SECOND QUARTER RESULTS

Highlights:
·  
Revenues of $45.3 million
·  
Operating income of $5.5 million, or 12.2% of revenues, excluding $1.5 million of transaction costs
·  
Net income of $6.3 million
·  
Diluted EPS of $0.44

EAST MILLSTONE, N.J. (July 30, 2009) Life Sciences Research, Inc. (NYSE Arca: LSR) announced today financial results for the three and six months ended June 30, 2009.

Revenues for the second quarter of 2009 were $45.3 million, 29.7% below second quarter 2008 revenues of $64.3 million.  Excluding the effect of exchange rate movements, revenues decreased 15.5%.  The second quarter of 2008 reflected record revenues and operating margins for the Company. Operating income for the quarter ended June 30, 2009 was $4.0 million, which included $1.5 million of expenses associated with the previously announced transaction for the Company to be acquired by Lion Holdings, an entity controlled by LSR’s Chairman and CEO, Andrew Baker. Excluding those costs, operating income was $5.5 million, or 12.2% of revenues, compared with $10.0 million, or 15.6% of revenues for the same period in the prior year.  The 2009 quarter included stock-based compensation expenses of $0.3 million or $0.02 per fully diluted share, compared with $0.6 million or $0.04 per fully diluted share in the 2008 quarter.  The 2009 quarter included Other Income of $4.4 million or $0.30 per fully diluted share associated with non-cash foreign exchange gains principally related to the Company’s dollar-based debt, compared with Other Income of $23 thousand in the 2008 quarter.  The Company reported net income for the quarter ended June 30, 2009 of $6.3 million or $0.44 per fully diluted share, compared with $7.3 million or $0.47 per fully diluted share for the quarter ended June 30, 2008.

Revenues for the six months ended June 30, 2009 were $93.3 million, 26.9% below revenues of $127.6 million for the same period in the prior year.  Excluding the effect of exchange rate movements, revenues decreased by 9.1%.  Operating Income for the six months ended June 30, 2009 was $9.9 million, which included $1.5 million of expenses associated with the previously announced transaction for the Company to be acquired by Lion Holdings. Excluding those costs, operating income was $11.4 million, or 12.2% of revenues, compared with $19.7 million, or 15.4% of revenues for the same period in the prior year.  The 2009 six-month period included stock-based compensation expenses of $0.6 million or $0.04 per fully diluted share, compared with $1.0 million or $0.07 per fully diluted share in the same period last year. Other Income in the current period was $4.3 million or $0.30 per fully diluted share, compared with Other Expense of $37 thousand in the prior year. The Company reported net income of $10.0 million or $0.69 per fully diluted share for the six months ended June 30, 2009, compared with $14.0 million or $0.91 per fully diluted share for the six months ended June 30, 2008.

Cash and cash equivalents as of June 30, 2009 were $39.5 million, up from $38.0 million as of March 31, 2009 and $36.5 million as of December 31, 2008.  Net days sales outstanding at June 30, 2009 were 26 days, compared with 27 days at March 31, 2009 and 30 days at December 31, 2008.  Capital expenditures totaled $2.2 million in the second quarter of 2009, compared with $5.0 million in the second quarter of 2008.  Capital expenditures for the six months ended June 30, 2009 totaled $4.3 million, compared with $9.8 million for the six months ended June 30, 2008.

Net new orders totaled $44.7 million for the second quarter of 2009.  This represented a book-to- bill ratio of 0.99 for the quarter.  Net new orders totaled $85.4 million for the six months ended June 30, 2009.  This represented a book-to-bill ratio of 0.92 for the six months ended June 30, 2009.  At June 30, 2009 backlog (booked on work) amounted to approximately $149 million.

Brian Cass, LSR’s President and Managing Director commented, “Whilst this remains a challenging time for our company and industry, I am encouraged by the confidence that many of our customers have expressed in their ability to develop greater numbers of new therapies and bring them to market. This will almost inevitably increase outsourcing and as a consequence refresh CRO order levels, possibly in the latter part of this year or into 2010. During this short-term softness in demand I would like to recognise the achievements of our staff, particularly for the imagination and commitment they have shown in controlling our costs so as to limit the impact on our operating margins and cash flow.”

On July 9, 2009, LSR announced that it had entered into a definitive merger agreement to be acquired by Lion Holdings, Inc, an entity controlled by LSR’s Chairman and CEO, Andrew Baker, for $8.50 per share in cash. The transaction is expected to close in the fourth quarter of 2009, and is subject to certain closing conditions, including stockholder approval.

Conference Call

LSR management will host an investment community conference call beginning at 9:00 a.m. Eastern time on July 31, 2009 to discuss these results and to answer questions. Shareholders and other interested parties may participate in the conference call by dialing (773) 756-0828 and entering passcode 9585404.  We suggest calling five minutes prior to the scheduled call.

A replay of the call will be available one hour after the call is completed until August 14, 2009, at 5:00 p.m. Eastern time.  The replay number is 402-998-1776 and the pass code is 73109.  A recording of the conference call will also be available on the Company website at www.lsrinc.net.


About Life Sciences Research

Life Sciences Research, Inc. is a global contract research organization providing product development services to the pharmaceutical, agrochemical and biotechnology industries.  LSR brings leading technology and capability to support its clients in non-clinical safety testing of new compounds in early stage development and assessment.  The purpose of this work is to identify risks to humans, animals or the environment resulting from the use or manufacture of a wide range of chemicals which are essential components of LSR's clients' products.  The Company's services are designed to meet the regulatory requirements of governments around the world.  LSR operates research facilities in the United States (the Princeton Research Center, New Jersey) and the United Kingdom (Huntingdon and Eye, England).

Forward Looking Statements

This announcement contains statements that may be forward-looking as defined by the Private Securities Litigation Reform Act of 1995.  These statements are based largely on LSR’s expectations and are subject to a number of risks and uncertainties, certain of which are beyond LSR’s control, as more fully described in the Company’s SEC filings, including its Form 10-K for the fiscal year ended December 31, 2008, as filed with the US Securities and Exchange Commission.

- tables to follow -

 
 

 
Life Sciences Research Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
Unaudited




(Dollars in thousands, except per share data)
 
3 months ended June 30
   
6 months ended June 30
 
   
2009
   
2008
   
2009
   
2008
 
                         
Net revenues
  $ 45,250     $ 64,330     $ 93,295     $ 127,557  
Cost of sales
    (33,321 )     (43,507 )     (67,609 )     (86,871 )
Gross profit
    11,929       20,823       25,686       40,686  
Selling, general and administrative expenses
    (6,428 )     (10,796 )     (14,294 )     (20,995 )
Acquisition-related expenses
    (1,500 )     -       (1,500 )     -  
Operating income
    4,001       10,027       9,892       19,691  
Interest income
    37       133       50       332  
Interest income, related parties
    110       123       215       247  
Interest expense
    (2,032 )     (2,360 )     (3,994 )     (4,664 )
Interest expense, related parties
    (732 )     (780 )     (1,448 )     (1,597 )
Other income/(expense)
    4,386       23       4,299       (37 )
Income before income taxes
    5,770       7,166       9,014       13,972  
Income tax benefit
    530       118       950       47  
Net income
  $ 6,300     $ 7,284     $ 9,964     $ 14,019  
                                 
                                 
Income per share
                               
-Basic
  $ 0.47     $ 0.58     $ 0.75     $ 1.11  
-Diluted
  $ 0.44     $ 0.47     $ 0.69     $ 0.91  
                                 
Weighted average number of common stock
                               
- Basic     (000’s)
    13,349       12,655       13,347       12,644  
- Diluted  (000’s)
    14,443       15,559       14,452       15,480  
                                 
                                 
                                 

 

 
 

 
Life Sciences Research Inc. and Subsidiaries
Condensed Consolidated Balance Sheets



(Dollars in thousands, except per share data)
 
June 30,
2009
(Unaudited)
   
December 31, 2008
(Audited)
 
ASSETS
           
Current assets:
           
Cash and cash equivalents
  $ 39,486     $ 36,493  
Accounts receivable, net
    24,364       19,607  
Unbilled receivables, net
    19,347       21,683  
Inventories
    2,600       2,854  
Prepaid expenses and other current assets (includes related parties of $1,969 and $985 in 2009 and 2008)
    6,290       5,031  
Total current assets
  $ 92,087     $ 85,668  
Property, plant and equipment, net
    69,128       63,610  
Goodwill
    3,126       2,684  
Intangible assets, net
    6,072       6,449  
Other assets, related parties
    2,488       3,074  
Deferred income taxes
    10,693       9,713  
Total assets
  $ 183,594     $ 171,198  
                 
LIABILITIES AND STOCKHOLDERS' DEFICIT
               
Current liabilities:
               
Accounts payable
  $ 11,791     $ 12,061  
Accrued payroll and other benefits
    3,597       3,882  
Accrued expenses and other liabilities
    25,093       25,921  
Short-term debt
    2,400       2,596  
Fees invoiced in advance
    29,803       27,681  
Total current liabilities
  $ 72,684     $ 72,141  
Long-term debt, net (includes related parties of $21,901 and $21,025 in 2009 and 2008)
    71,982       71,943  
Deferred gain on disposal of US property
    8,307       8,467  
Pension liabilities
    38,320       33,859  
Total liabilities
  $ 191,293     $ 186,410  
                 
Commitments and contingencies
               
Stockholders' deficit
               
Preferred Stock, $0.01 par value.  Authorized: 5,000,000
               
Issued and outstanding: None
    -       -  
Non-Voting Common Stock, $0.01 par value.  Authorized: 5,000,000
               
Issued and outstanding: None
    -       -  
Voting Common Stock, $0.01 par value.  Authorized: 50,000,000
               
Issued and outstanding at June 30, 2009: 13,349,095
               
(December 31, 2008: 13,345,495)
    133       133  
Paid in capital
    90,331       89,717  
Accumulated other comprehensive loss
    (48,750 )     (45,686 )
Accumulated deficit
    (49,413 )     (59,376 )
Total stockholders' deficit
  $ (7,699 )   $ (15,212 )
Total liabilities and stockholders' deficit
  $ 183,594     $ 171,198  

 
 

 
Life Sciences Research Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
Unaudited


(Dollars in thousands)
 
June 30, 2009
   
June 30, 2008
 
Cash flows from operating activities:
           
Net income
  $ 9,964     $ 14,019  
Adjustments to reconcile net income to net cash provided by/(used in) operating activities
               
Depreciation and amortization
    4,123       4,938  
Amortization of gain on disposal of US property
    (160 )     (160 )
Non-cash compensation expense associated with employee stock compensation plans
    594       1,045  
Foreign exchange (gain)/loss on March 2006 Financing
    (5,201 )     21  
Foreign exchange loss on intercompany balances
    902       16  
Deferred income tax benefit
    (950 )     (47 )
Provision for losses on accounts receivable
    183       51  
Amortization of debt issue and financing costs included in interest expense
    1,674       1,947  
Changes in operating assets and liabilities:
               
Accounts receivable, unbilled receivables and prepaid expenses
    879       (2,031 )
Inventories
    468       (140 )
Accounts payable, accrued expenses and other liabilities
    (5,163 )     (6,013 )
Fees invoiced in advance
    (1,099 )     (5,044 )
Defined benefit pension plan liabilities
    (407 )     (1,952 )
Net cash provided by operating activities
  $ 5,807     $ 6,650  
                 
Cash flows used in investing activities:
               
Purchase of property, plant and equipment
    (4,257 )     (9,839 )
Payment for acquisition
    -       (1,779 )
Net cash used in investing activities
  $ (4,257 )   $ (11,618 )
                 
Cash flows used in financing activities:
               
Proceeds from issue of Voting Common Stock
    20       156  
Repayments of long-term borrowings
    (1,200 )     (1,200 )
Repayments of short-term borrowings
    (73 )     (373 )
Net cash used in financing activities
  $ (1,253 )   $ (1,417 )
                 
Effect of exchange rate changes on cash and cash equivalents
    2,696       252  
Increase/(decrease) in cash and cash equivalents
    2,993       (6,133 )
Cash and cash equivalents at beginning of period
    36,493       36,223  
Cash and cash equivalents at end of period
  $ 39,486     $ 30,090  

 
Supplementary Disclosures:
           
Interest paid
  $ 3,755     $ 4,084  
Income taxes paid
  $ 273     $ 89